1 May 2023 - Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.

In 2021, the European Medicines Agency approved Trodelvy for triple-negative breast cancer. Subsequently, beginning in December 2021, the Dutch VWS placed Trodelvy in a so-called lock, which meant it was temporarily excluded from reimbursement because its total costs to the healthcare system for all current and future indications were projected to exceed €40 million annually. 

Read Forbes article